TWI587863B - A probiotic entrapping particle - Google Patents

Description

Probiotic bacteria embedded particles

The invention relates to a probiotic bacteria embedded particle, in particular to an embedded particle of a probiotic bacteria embedded in a fungal hyphae.

Probiotics generally refer to bacteria that use carbohydrates for fermentation to produce large amounts of lactic acid. Probiotics prevent the invasion of pathogens by attaching to the gut of the host and have positive benefits for the host. The probiotics commonly found on the market today are lactic acid bacteria and yeasts, while the probiotics are mainly liquid, powder or hard capsules. Among them, since the product type of probiotics will affect its efficacy, it plays an important part in development and production.

Taking lactic acid bacteria as an example, for example, Republic of China Invention Patent Publication No. 587098, discloses a lactic acid bacteria capable of improving immunity, comprising any one or more of the following biologically pure cultures stimulating an immunological concentration: Lactobacillus rhamnosus HN001 CCRC 910107; Lactobacillus licheniformis HN067 CCRC 910108; Bifidobacterium lactis HN019 CCRC 910110 or Lactobacillus acidophilus HN017 CCRC 910109, and a physiologically acceptable excipient or diluent, wherein the excipient or The diluent is a food product, and the food is fermented milk, yogurt, cheese, dairy drink or milk powder. Or, as disclosed in the Chinese Patent Publication No. I451871, a food composition for inhibiting an inflammatory reaction, comprising: a plurality of strains of lactic acid bacteria comprising Lactobacillus salivarius AP-32 strain, accession number BCRC 910437, road Lactobacillus reuteri TE-33 strain, accession number BCRC 910441, Lactobacillus acidophilus F-1 strain, accession number BCRC 910469 and buckthorn Lactobacillus rhamnosus CT-53 strain, accession number BCRC 910468, wherein the lactic acid bacteria strain has stomach acid, bile salt and mold inhibitor Clotrimazole tolerance; and physiologically acceptable one shape Or a diluent, wherein the excipient or the diluent is fermented milk, yogurt, cheese, milk powder for milk, tea or coffee. In the above prior art, the lactic acid bacteria dosage form is a liquid or powder which is not embedded, because the lactic acid bacteria are sensitive to the pH of the environment, and the stomach acid and bile of the human body have a bactericidal effect, and the un-encapsulated lactic acid bacteria enter the human body and the bacteria body. It is easy to be destroyed, but it can not exert its proper curative effect. Secondly, due to the lack of embedding, the stability of lactic acid bacteria is insufficient, and the number of viable bacteria is easily reduced, resulting in short storage period and long-lasting survival.

In view of the above shortcomings, another lactic acid bacteria embedded in capsules, such as the Republic of China Invention Patent Publication No. M384660, discloses a LS66 capsule combination structure capable of inhibiting the growth of excess fat in the body, comprising a body, more than one LS66 spore lactic acid bacteria and one a coating layer, the body comprises an upper capsule and a lower capsule, and the upper capsule and the lower capsule are combined to form an accommodating space therein, and the LS66 spore lactic acid bacteria is filled in the accommodating space, and the coating layer is coated Deployed on the inner surface of the body, wherein the coating layer is an activator. However, the hard-capsule-embedded lactic acid bacteria can protect the cells from the acidic stomach environment, but the hard capsules are not easily dissolved in the intestinal tract, making the timing of releasing the cells unstable, and also having the problem of being inferior.

In addition to the above product types of liquids, powders and hard capsules, there are also crystal spheres used as materials for coating probiotics. However, although they have the advantages of durability and resistance to stomach acid and bile, their thermal stability is not good. And it takes about six hours to dissolve in the intestine, and in addition, it is expensive.

The main object of the present invention is to solve the problems of conventional liquid and powder probiotic products, which are not resistant to stomach acid, bile, and lack of stability and long-lasting problems, while hard-encapsulated probiotics are not easily dissolved in the intestine and are not durable. The problem of survival is that the crystal ball is expensive for embedding probiotics.

To achieve the above object, the present invention provides a probiotic bacteria-embedded particle comprising a probiotic sclerotium; a gelatinous substance layer covering the probiotic sclerotium; and a fungal mycelium shell covering the gelatinous substance layer.

In order to achieve the above object, the present invention further provides a method for producing a probiotic-embedded particle, comprising the steps of: providing a probiotic sclerotium; coating a gelatinous substance on the probiotic sclerotium at a first wind pressure; The gelatinous substance is dried to form a layer of a gelatinous substance; a fungal hyphae is coated with the layer of the gelatinous substance by a second wind pressure; and the fungal hyphae are dried to form a fungal mycelium shell layer.

In order to achieve the above object, the present invention further provides a probiotic-embedded particle obtained by the aforementioned method.

From the above, the present invention has at least the following effects compared to the prior art:

1. Using the fungal mycelial shell layer and the gelatinous substance layer as an embedding structure, the probiotic bacteria can be effectively protected, and the probiotic sclerotium of the probiotic bacteria embedded in the stomach can retain its activity without being damaged in the gastric acid environment. It can reach the small intestine and large intestine smoothly, and is more soluble in the alkaline intestinal environment.

Secondly, the fungal mycelium shell contains fungal nutrients, which can provide health care effects when the human body is ingested, such as alleviating allergies, lowering blood pressure, lowering blood sugar, and the like.

Third, by the structure of the fungal mycelial shell layer, the stability and storage stability of the secondary processing of the probiotic bacteria embedded particles can be increased.

4. The probiotic sclerotium has the functions of adjusting the constitution, maintaining the functions of the digestive tract and changing the intestinal bacteria, and the manufacturing cost of the probiotic bacteria embedded particles is lower; in addition, the production cost of the probiotic bacteria embedded particles of the invention is higher The crystal ball is embedded in a lower cost and is easy to mass produce.

10‧‧‧Probiotic sclerotia

11‧‧·bacteria stabilizer

12‧‧‧Probiotics

20‧‧‧Colloidal layer

30‧‧‧Fungi mycelium shell

FIG. 1 is a schematic perspective view of an embodiment of the present invention.

"Fig. 2" is a schematic view of the A-A section of Fig. 1.

The detailed description and technical content of the present invention will now be described as follows:

Referring to FIG. 1 and FIG. 2, respectively, a schematic perspective view of an embodiment of the present invention and a cross-sectional view of AA of FIG. 1 are provided. The present invention provides a probiotic bacteria embedded particle comprising a probiotic sclerotium. 10. A gelatinous substance layer 20 and a fungal mycelium shell 30, the gelatinous substance layer 20 coating an outer surface of the probiotic sclerotium 10, and the fungal mycelium shell layer 30 coating the gelatinous substance layer An outer surface of 20, in the present embodiment, the probiotic sclerotium 10, the gelatinous substance layer 20 and the fungal mycelium shell layer 30 sequentially form a multi-layer concentric spherical structure from the inside to the outside, thereby making the probiotic bacteria The embedded particles are spherical, and the spherical shape referred to herein includes a completely spherical surface with a smooth surface and a polyhedron close to the true sphere.

As shown in FIG. 2, in an embodiment of the present invention, the probiotic sclerotia 10 includes a bacteria stabilizer 11 and a plurality of probiotics 12 dispersed in the bacteria stabilizer 11, and the probiotics 12 include a plurality of lactic acid bacteria powders, wherein the bacteria stabilizer 11 may be trehalose, milk powder, polydextrose, monosodium glutamate, pyrophosphate, vitamins, arginine or a combination thereof, and the probiotics 12 may be Lactobacillus acidophilus ( Lactobacillus acidophilus), Bifidobacterium lactis, calf Enterococcus faecium, Bifidobacterium bifidum or a combination of the foregoing. The composition of the gelatinous substance layer 20 may be Shellac, Hydroxypropylmethylcellulose phthalate (HPMCP), Zein, Gelatin, Gum arabic, Collagen, Alginic acid sodium or a combination thereof, the composition of the fungal mycelium shell 30 can be Ganoderma lucidum, Antrodia camphorata, Red peony, Cordyceps sinensis, Hericium erinaceus, Armillaria, and sassafras , Agaricus blazei, Cordyceps militaris, Maitake, mulberry or a combination of the foregoing.

The invention further provides a method for manufacturing a probiotic bacteria embedded particle, which can be carried out by using an embedding device and a low temperature spray flow layer technology, the method comprising the following steps:

Step A: providing a probiotic nucleus 10, in one embodiment of the present invention, the probiotic nucleus 10 comprises a bacteria stabilizer 11 and a plurality of probiotics 12 dispersed in the bacteria stabilizer 11, the bacteria stabilizer The composition of 11 and the probiotic 12 is as described above.

Step B: coating a gelatinous substance on the probiotic nucleus 10 with a first wind pressure. In an embodiment of the invention, the first wind pressure is between 0.5 kg/cm ² and 2 kg/cm ² . And the probiotic sclerotium 10 is supplied to a nozzle opening that produces the first wind pressure at a feed rate between 3 rpm and 30 rpm.

Step C: drying the gelatinous substance to form a gelatinous substance layer 20, in an embodiment of the present invention, between a relative humidity of between 3% and 30% and a temperature between 20 ° C and 55 ° C The temperature is dried.

Step D: coating a fungal hyphae with the gelatinous substance layer 20 by a second wind pressure. In one embodiment of the invention, the second wind pressure is between 1 kg/cm ² and 3 kg/cm ² .

Step E: drying the fungal hyphae to form a fungal mycelium shell 30, in one embodiment of the invention, at a relative humidity of between 3% and 30% and a temperature between 20 ° C and 55 ° C The temperature between them is dried.

In an embodiment of the invention, the preparation of the probiotic nucleus 10 comprises the following steps:

Step A-1: cultivating a probiotic strain in a fermenter to obtain the probiotic 12, the fermentation tank being at a temperature between 32 ° C and 40 ° C and containing between 1 wt.% and 5 wt.% of glucose a peptone between 0.1 wt.% and 2 wt.% and a culture solution of the yeast extract between 0.1 wt.% and 3 wt.%. The aforementioned concentration means the concentration of each culture material in the weight percentage of the fermentation tank.

Step A-2: The probiotic 12 is subjected to a freeze-drying step at a temperature between 10 ° C and 30 ° C.

Step A-3: adding the bacteria stabilizer 11 to the probiotic 12 to obtain the probiotic nucleus 10, the bacteria stabilizer 11 having a weight of between 5 wt.% and 15 wt.% with respect to the probiotic sclerotium 10. percentage. According to the actual production results, the probiotics 12 can produce more than 22Kg of bacteria, and the number of bacteria reaches 10 ¹¹ cfu/g or more.

In order to further verify the efficacy of the probiotic-embedded granules of the present invention, reference is made to the following tests conducted in accordance with the present invention, which are for illustrative purposes only and are not intended to limit the scope of the invention. The following tests included stability testing of probiotics for different spray conditions, stability testing of probiotics at different drying temperatures, moisture content and water activity testing of probiotics, and testing for induction of animal immune activity.

Probiotic stability test - effects of different spray conditions

The test consisted of three groups of comparison and experimental groups. Comparison group 1 and experiment group 1 used Lactobacillus acidophilus, comparison group 2 and experimental group 2 used Enterococcus faecium, comparison group 3 and experimental group. 3 Using Bifidobacterium lactis, the embedding process adopts low-temperature spray flow layer technology, with the spray time and spray concentration as variables. The comparison group consisted of unembedded probiotics and probiotics embedding the gelatinous material layer only by spray technique, without embedding the fungal mycelium shell, and the concentration of the gelatinous substance sprayed was 20wt.%, the rest is solvent, spray time is 30min, 45min, 60min. In the experimental group, the spray concentration of the embedded gelatinous substance layer was also 20 wt.%, and when the fungal mycelium shell was embedded, the sprayed fungal hyphae concentrations were 10 wt.%, 15 wt.%, 20 wt.%, 25 wt. .%, the rest are solvents, the spray time of each group is 30min, 45min, 60min, after the completion of the measurement of the initial number of probiotics and the number of probiotics after 1 month, 2 months, 3 months. Table 1, Table 2, and Table 3 show the number of probiotics in Comparative Group 1 and Experimental Group 1, Comparative Group 2, and Experimental Group 2, Comparative Group 3, and Experimental Group 3, respectively, under different conditions. In addition, the experimental group 3 has only partial data.

It can be seen from the above that the survival rate of the probiotics without embedding or embedding the gel-like substance layer is significantly reduced after 3 months, even less than 1%, and the embedded particle structure of the present invention can be effectively protected. Probiotic activity and stability; on the other hand, different spray times will affect the stability of probiotics. If the spray time is too long, it will be thrown in the instrument, which will damage the probiotics and affect their survival rate.

Probiotic stability test - effects of different drying temperatures

This test is to further observe the effect of different drying temperatures on the stability of probiotics according to the best results in the aforementioned probiotic stability test. Among them, the experimental group 1 selects the spraying time as 30 minutes and the spray concentration is 15wt.%. Named as experimental group 1-1; experimental group 2 selected spray time of 30 minutes, spray concentration of 10wt.%, and named experimental group 2-1; experimental group 3 selected spray time of 30 minutes, spray concentration of 20wt.% And named experimental group 3-1. The drying temperatures were 40 ° C, 50 ° C, and 60 ° C, respectively. Table 4 shows that after different drying temperatures, the experimental group 1-1, the experimental group 2-1 The number of probiotics in the experimental group 3-1 is shown in Table 4. As is clear from the table below, the results were best when the drying temperature was 40 °C.

Probiotic stability test - moisture content and water activity

The steps for moisture content testing are as follows:

Step F-1: 3 g of the probiotic bacteria embedded particles of the present invention were taken and placed in a sample dish.

Step F-2: The lid of the sample dish was opened and placed in an oven at 105 ° C for 4 hours to evaporate the moisture of the probiotic bacteria, and then the lid was covered in an oven and the sample dish was taken out.

Step F-3: The sample dish is placed in a closed container and the desiccant is placed in a closed container. After the temperature of the probiotic bacteria embedded particles is balanced with the room temperature, the probiotic bacteria embedded particles are taken out and weighed.

Step F-4: After weighing, the sample dish is placed in an oven and dried at 105 ° C for 1 hour, and then the sample dish is placed in the closed container to be warmed up, and the weight is taken out.

Step F-5: Repeat step F-4 until the weight of the probiotic-embedded particles does not change, and calculate the moisture content according to the following formula: moisture content = (weight before drying - heavy after drying) / weight after drying × 100%.

The results of the test showed that the moisture content of the probiotic embedded particles was less than 8%, indicating that the probiotic embedded particles of the present invention have excellent storage resistance.

The water activity test is to analyze 2 g of the probiotic embedded particles of the present invention using a water activity analyzer, and the results show that the water activity is less than 0.1, indicating that the probiotic embedded particles of the present invention can improve the bacterial or mold spoilage problem. .

Test for inducing animal immune activity

This test compares the effects of the probiotic embedded particles of the present invention and the unembedded probiotics on the induction of animal immune activity. In this test, mice were used as experimental subjects. The experimental group was fed with the probiotic bacteria embedded particles of the present invention for 30 days, and the comparison group was fed with probiotic bacteria without fungal hyphae for 30 days. The group is not fed probiotics. At the end of the feeding, the spleen cells of the mice were treated with phlegm, which was Concanavalin A (Con A) and Lipopolysaccharide (LPS). The results showed that under the stimulation of ConA, the lymphocyte proliferation (P<0.01) of the experimental group compared with the control group (no feeding) was higher than that of the control group (no feeding) (P<0.1). On the other hand, under the stimulation of LPS, the experimental group also increased lymphocyte proliferation (P < 0.1), and the results are shown in Table 5.

From the above, it can be seen that the probiotic bacteria embedded particles of the present invention metabolize the fungal polysaccharide after biological feeding, which has an effect on the immunomodulatory activity.

In summary, the present invention utilizes the fungal mycelium shell layer and the gelatinous substance layer as an embedding structure, which can effectively protect the probiotic bacteria, and the probiotic nucleus of the probiotic bacteria embedded in the stomach acid environment, retaining the probiotic bacterium Active without damage, can reach the small intestine and large intestine smoothly, and is more easily dissolved in the alkaline intestinal environment; secondly, the fungal mycelium shell contains fungal nutrients, which can be provided when the human body ingests The effects of health care, such as slowing allergies, lowering blood pressure, lowering blood sugar, etc.; The structure of the fungal mycelial shell layer can increase the stability and storage stability of the secondary processing of the probiotic bacteria embedded particles; the probiotic sclerotium has the functions of adjusting body constitution, maintaining digestive tract function and changing intestinal bacteria, and the probiotic The manufacturing cost of the bacteria-embedded particles is low; in addition, the production cost of the probiotic-embedded particles of the present invention is lower than that of the crystal ball embedding, and is easy to mass-produce.

The present invention has been described in detail above, but the foregoing is only a preferred embodiment of the present invention, and is not intended to limit the scope of the invention. That is, the equivalent changes and modifications made by the scope of the present application should remain within the scope of the patent of the present invention.

10‧‧‧Probiotic sclerotia

11‧‧·bacteria stabilizer

12‧‧‧Probiotics

20‧‧‧Colloidal layer

30‧‧‧Fungi mycelium shell

Claims (8)

a probiotic embedded particle comprising: a probiotic sclerotium; a gelatinous substance layer covering the probiotic sclerotium; and a fungal mycelium shell covering the gelatinous substance layer and directly contacting the gelatinous substance layer contact. The probiotic granule according to claim 1, wherein the probiotic sclerotium comprises a bacteria stabilizer and a probiotic dispersed in the bacteria stabilizer. The probiotic-embedded particles according to claim 2, wherein the bacteria stabilizer is selected from the group consisting of trehalose, milk powder, polydextrin, monosodium glutamate, pyrophosphate, vitamins and arginine. The probiotic-embedded granule of claim 2, wherein the probiotic comprises a plurality of probiotic powders. The probiotic bacteria-embedded particles according to claim 2, wherein the probiotics are selected from the group consisting of Lactobacillus acidophilus, Enterococcus faecium, B. glutinosa and Bifidobacterium. The probiotic-embedded particles according to claim 1, wherein the composition of the gelatinous substance layer is selected from shellac, hydroxypropylmethylcellulose, zein, gelatin, gum arabic, collagen and seaweed. A group consisting of sodium. The probiotic bacteria embedded particles according to claim 1, wherein the fungal mycelium shell layer is selected from the group consisting of ganoderma lucidum, anthocyanin, red peony, cordyceps sinensis, hericium erinaceus, honey fungus, sassafras, jasmine, A group of Cordyceps, Maitake and Sanghuang. The probiotic bacteria-embedded particles according to claim 1, wherein the probiotic sclerotium, the gelatinous substance layer and the fungal mycelial shell layer sequentially form a multi-layer concentric spherical structure from the inside to the outside.